$1.71
-0.05[-2.84%]
At close: Apr 25
$1.71
0[0.00%]
After Hours: 6:54PM EDT
Xeris Biopharma Holdings
(NASDAQ:XERS)Xeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, Predictions
Xeris Biopharma Holdings Inc has a consensus price target of $4.93, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co. on March 28, 2024, March 7, 2024, and November 13, 2023. With an average price target of $5.5 between Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 221.64% upside for Xeris Biopharma Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Piper Sandler
Craig-Hallum
SVB Leerink
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Xeris Biopharma Holdings
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 192.4% | Oppenheimer | Leland Gershell | → $5 | Initiates | → Outperform | Get Alert |
| 03/07/2024 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | HC Wainwright & Co. | Oren Livnat | $5.5 → $6 | Maintains | Buy | Get Alert |
| 11/13/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 221.64% | HC Wainwright & Co. | Oren Livnat | $6 → $5.5 | Maintains | Buy | Get Alert |
| 11/10/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 133.92% | Piper Sandler | David Amsellem | $5 → $4 | Maintains | Overweight | Get Alert |
| 08/28/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 163.16% | Craig-Hallum | Robin Garner | → $4.5 | Initiates | → Buy | Get Alert |
| 08/09/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | HC Wainwright & Co. | Oren Livnat | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | HC Wainwright & Co. | Oren Livnat | → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/09/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | HC Wainwright & Co. | Oren Livnat | → $6 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 192.4% | SVB Leerink | Roanna Ruiz | $6 → $5 | Maintains | Outperform | Get Alert |
| 10/21/2022 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 133.92% | Jefferies | Glen Santangelo | → $4 | Assumes | → Buy | Get Alert |
| 04/28/2022 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 280.12% | Craig-Hallum | Robin Garner | → $6.5 | Initiates | → Buy | Get Alert |
| 03/16/2022 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | Mizuho | Vamil Divan | $8 → $6 | Maintains | Buy | Get Alert |
| 02/16/2022 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | SVB Leerink | Roanna Ruiz | $8 → $6 | Maintains | Outperform | Get Alert |
| 12/31/2021 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 367.84% | SVB Leerink | Roanna Ruiz | $6 → $8 | Maintains | Outperform | Get Alert |
| 12/31/2021 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 215.79% | HC Wainwright & Co. | Oren Livnat | $4.25 → $5.4 | Maintains | Buy | Get Alert |
| 11/17/2021 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 250.88% | SVB Leerink | Roanna Ruiz | — | Initiates | → Outperform | Get Alert |
| 10/29/2021 | XERS | Buy Now | Xeris Biopharma Holdings | $1.71 | 133.92% | HC Wainwright & Co. | Oren Livnat | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Xeris Biopharma Holdings (XERS)?
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by Oppenheimer on March 28, 2024. The analyst firm set a price target for $5.00 expecting XERS to rise to within 12 months (a possible 192.40% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ: XERS) was provided by Oppenheimer, and Xeris Biopharma Holdings initiated their outperform rating.
When was the last upgrade for Xeris Biopharma Holdings (XERS)?
There is no last upgrade for Xeris Biopharma Holdings.
When was the last downgrade for Xeris Biopharma Holdings (XERS)?
There is no last downgrade for Xeris Biopharma Holdings.
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a initiated with a price target of $0.00 to $5.00. The current price Xeris Biopharma Holdings (XERS) is trading at is $1.71, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.